These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33098154)

  • 41. Safety of ferumoxytol in patients with anemia and CKD.
    Singh A; Patel T; Hertel J; Bernardo M; Kausz A; Brenner L
    Am J Kidney Dis; 2008 Nov; 52(5):907-15. PubMed ID: 18824288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of a motion-robust 2D chemical shift-encoded technique for R2* and field map quantification in ferumoxytol-enhanced MRI of the placenta in pregnant rhesus macaques.
    Zhu A; Reeder SB; Johnson KM; Nguyen SM; Golos TG; Shimakawa A; Muehler MR; Francois CJ; Bird IM; Fain SB; Shah DM; Wieben O; Hernando D
    J Magn Reson Imaging; 2020 Feb; 51(2):580-592. PubMed ID: 31276263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Feasibility of ferumoxytol-enhanced neonatal and young infant cardiac MRI without general anesthesia.
    Lai LM; Cheng JY; Alley MT; Zhang T; Lustig M; Vasanawala SS
    J Magn Reson Imaging; 2017 May; 45(5):1407-1418. PubMed ID: 27678106
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brain iron deposition after Ferumoxytol-enhanced MRI: A study of Porcine Brains.
    Theruvath AJ; Aghighi M; Iv M; Nejadnik H; Lavezo J; Pisani LJ; Daldrup-Link HE
    Nanotheranostics; 2020; 4(4):195-200. PubMed ID: 32637297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of Blood Pool Contrast Agent Administration in Children and Young Adults.
    Rigsby CK; Popescu AR; Nelson P; Orr RJ; Boylan EE; Schoeneman S; deFreitas RA
    AJR Am J Roentgenol; 2015 Nov; 205(5):1114-20. PubMed ID: 26496560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Steady-state ferumoxytol-enhanced MRI: early observations in benign abdominal organ masses and clinical implications.
    Shahrouki P; Felker ER; Raman SS; Jeong WK; Lu DS; Finn JP
    Abdom Radiol (NY); 2022 Jan; 47(1):460-470. PubMed ID: 34689252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 2015 Update on Acute Adverse Reactions to Gadolinium based Contrast Agents in Cardiovascular MR. Large Multi-National and Multi-Ethnical Population Experience With 37788 Patients From the EuroCMR Registry.
    Bruder O; Schneider S; Pilz G; van Rossum AC; Schwitter J; Nothnagel D; Lombardi M; Buss S; Wagner A; Petersen S; Greulich S; Jensen C; Nagel E; Sechtem U; Mahrholdt H
    J Cardiovasc Magn Reson; 2015 Jul; 17(1):58. PubMed ID: 26170152
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Unveiling the next generation of MRI contrast agents: current insights and perspectives on ferumoxytol-enhanced MRI.
    Si G; Du Y; Tang P; Ma G; Jia Z; Zhou X; Mu D; Shen Y; Lu Y; Mao Y; Chen C; Li Y; Gu N
    Natl Sci Rev; 2024 May; 11(5):nwae057. PubMed ID: 38577664
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.
    Kowalczyk M; Banach M; Rysz J
    J Nephrol; 2011; 24(6):717-22. PubMed ID: 21956770
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ferumoxytol magnetic resonance angiography: a dose-finding study in patients with chronic kidney disease.
    Stoumpos S; Hennessy M; Vesey AT; Radjenovic A; Kasthuri R; Kingsmore DB; Mark PB; Roditi G
    Eur Radiol; 2019 Jul; 29(7):3543-3552. PubMed ID: 30919067
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute adverse events in cardiac MR imaging with gadolinium-based contrast agents: results from the European Society of Cardiovascular Radiology (ESCR) MRCT Registry in 72,839 patients.
    Uhlig J; Lücke C; Vliegenthart R; Loewe C; Grothoff M; Schuster A; Lurz P; Jacquier A; Francone M; Zapf A; Schülke C; ; May MS; Bremerich J; Lotz J; Gutberlet M;
    Eur Radiol; 2019 Jul; 29(7):3686-3695. PubMed ID: 31041566
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence and Risk Factors for Gadolinium-Based Contrast Agent Immediate Reactions.
    Costello JR; Kalb B; Martin DR
    Top Magn Reson Imaging; 2016 Dec; 25(6):257-263. PubMed ID: 27748714
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute adverse reactions to magnetic resonance contrast media--gadolinium chelates.
    Li A; Wong CS; Wong MK; Lee CM; Au Yeung MC
    Br J Radiol; 2006 May; 79(941):368-71. PubMed ID: 16632615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Iodinated Contrast Media Substitution to Prevent Recurrent Hypersensitivity Reactions: A Systematic Review and Meta-Analysis.
    Umakoshi H; Nihashi T; Takada A; Hirasawa N; Ishihara S; Takehara Y; Naganawa S; Davenport MS; Terasawa T
    Radiology; 2022 Nov; 305(2):341-349. PubMed ID: 35852428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Iron Sucrose as MRI Contrast Agent in Ischemic Stroke Model.
    Wu S; Zhang H; Wang J; Li X; Gao X; Fang Z; Qu J; Wu Y; Ren Y; Rui W; Zhang J; Yao Z
    J Magn Reson Imaging; 2020 Sep; 52(3):836-849. PubMed ID: 32112623
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Efficacy of Ferumoxytol for Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials.
    Shao Y; Luo W; Xu H; Zhang L; Guo Q
    Acta Haematol; 2019; 142(3):125-131. PubMed ID: 31434073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.
    Schiller B; Bhat P; Sharma A
    Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survey of gadolinium-based contrast agent utilization among the members of the Society for Pediatric Radiology: a Quality and Safety Committee report.
    Blumfield E; Moore MM; Drake MK; Goodman TR; Lewis KN; Meyer LT; Ngo TD; Sammet C; Stanescu AL; Swenson DW; Slovis TL; Iyer RS
    Pediatr Radiol; 2017 May; 47(6):665-673. PubMed ID: 28283728
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min.
    Auerbach M; Strauss W; Auerbach S; Rineer S; Bahrain H
    Am J Hematol; 2013 Nov; 88(11):944-7. PubMed ID: 23828252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
    Neuwelt EA; Várallyay CG; Manninger S; Solymosi D; Haluska M; Hunt MA; Nesbit G; Stevens A; Jerosch-Herold M; Jacobs PM; Hoffman JM
    Neurosurgery; 2007 Apr; 60(4):601-11; discussion 611-2. PubMed ID: 17415196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.